Emergent BioSolutions Inc. to be Added to the S&P MidCap 400 Index
July 21 2020 - 4:45PM
Emergent BioSolutions Inc. (NYSE: EBS) today announced that
Standard & Poor’s (S&P) has indicated that the company will
be added to the S&P MidCap 400® index, effective prior to the
open of trading on Friday, July 24. The company will be classified
under S&P’s Global Industry Classification Standard (GICS)
Biotechnology Sub-Industry index.
“The addition of Emergent to the S&P MidCap 400 is an
important milestone as we continue on our growth trajectory,” said
Richard S. Lindahl, executive vice president and chief financial
officer of Emergent BioSolutions. “This move reflects our strong
progress as a global life sciences company committed to addressing
public health threats, and our efforts to maximize shareholder
value by growing revenues and prudently reinvesting in our
business.”
The S&P MidCap 400® provides investors with a benchmark for
mid-sized companies. The index, which is distinct from the
large-cap S&P 500®, measures the performance of profitable
mid-sized companies, reflecting the distinctive risk and return
characteristics of this market segment.
About Emergent BioSolutionsEmergent
BioSolutions is a global life sciences company whose mission is to
protect and enhance life. Through our specialty products and
contract development and manufacturing services, we are dedicated
to providing solutions that address public health threats. Through
social responsibility, we aim to build healthier and safer
communities. We aspire to deliver peace of mind to our patients and
customers so they can focus on what’s most important in their
lives. In working together, we envision protecting or enhancing 1
billion lives by 2030. For more information visit
www.emergentbiosolutions.com. Find us on LinkedIn and follow us on
Twitter @emergentbiosolu and Instagram @life_at_emergent.
Safe Harbor StatementThis press release
includes forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Any statements,
other than statements of historical fact, including, without
limitation, statements related to our continued growth trajectory,
maximizing shareholder value, growing revenues and prudently
reinvesting in our business are forward-looking statements. These
forward-looking statements are based on our current intentions,
beliefs and expectations regarding future events. We cannot
guarantee that any forward-looking statement will be accurate.
Investors should realize that if underlying assumptions prove
inaccurate or unknown risks or uncertainties materialize, actual
results could differ materially from our expectations. Investors
are, therefore, cautioned not to place undue reliance on any
forward-looking statement. Any forward-looking statements speak
only as of the date of this press release, and, except as required
by law, we do not undertake to update any forward-looking statement
to reflect new information, events or circumstances.
There are a number of important factors that could cause our
actual results to differ materially from those indicated by such
forward-looking statements, including, but not limited to, the
impact of global economic conditions and public health crises and
epidemics, such as the impact from the global pandemic that arose
from the novel strain of coronavirus (SARS-CoV-2) causing COVID-19
disease; availability of U.S. government funding for procurement
for our products; our ability to perform under our contracts; our
ability to secure follow-on procurement contracts to replace
procurement contracts that have expired or will be expiring; our
ability and the ability of our collaborators to enforce patents
related to NARCAN Nasal Spray; our ability to obtain and maintain
regulatory approvals or authorizations for our product candidates
and the timing of such regulatory matters; the safety and
effectiveness of the current COVID-19 product candidates we are
working on; the success of our commercialization, marketing and
manufacturing capabilities and strategy. The foregoing sets forth
many, but not all, of the factors that could cause actual results
to differ from our expectations in any forward-looking statement.
Investors should consider this cautionary statement as well as the
risk factors identified in our periodic reports filed with the
Securities and Exchange Commission when evaluating our
forward-looking statements.
Investor Contact:Robert G. BurrowsVice
President, Investor Relations240-631-3280BurrowsR@ebsi.com
Media Contact:Miko B. NeriSenior Director,
Global Communications & Public
Affairs240-631-3392NeriM@ebsi.com
Emergent Biosolutions (NYSE:EBS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Emergent Biosolutions (NYSE:EBS)
Historical Stock Chart
From Sep 2023 to Sep 2024